Optimizing Outcomes in Patients With RCC: Translating Evidence to Clinical Practice
May 22nd 2023Expert panelists from the UT Southwestern Medical Center review real world patient cases of renal cell carcinoma to illustrate recent clinical data and exhibit how it has been applied at their institution.
My Treatment Approach: Metastatic Castration-Resistant Prostate Cancer
April 17th 2023Andrew Armstrong, MD, and Matthew Manning, MD, review the profiles of three patients with metastatic castration-resistant prostate cancer (mCRPC) and discuss how they would have approached their treatment, given recent advances in radiotherapy and other options in the field.
Emerging Treatment Modalities in Metastatic Breast Cancer: Highlights from SABCS 2022 and Beyond
January 30th 2023Komal Jhaveri, MD, FACP, and Paolo Tarantino, MD, discuss updates in the treatment of metastatic breast cancer (mBC) from SABCS 2022 and other recent meetings, and how to best incorporate recent data into clinical practice.
Role of Immunotherapy in Patients with NSCLC: Emerging Biomarkers
December 22nd 2022Expert oncologist Martin Dietrich, MD, PhD, shares his excitement for an upcoming program wherein he and Meghan Mooradian, MD, highlight the evolving role of immunotherapy and biomarker-driven therapy in non-small cell lung cancer.
Recent Advances in The Treatment of Multiple Myeloma: Expert and Patient Perspectives
December 19th 2022Shaji Kumar, MD, and Krina Patel, MD, discuss key updates in the diagnosis and treatment of multiple myeloma. Jenny Ahlstrom, a patient, and Bonnie Falbo, a caregiver and patient advocate, share their personal journeys with multiple myeloma.
My Treatment Approach: Relapsed/Refractory Follicular Lymphoma
October 27th 2022Brian Hill, MD, PhD and Lori Leslie, MD, discuss their respective treatment approaches to relapsed/refractory follicular lymphoma (R/R FL), sharing patient cases, reviewing treatment options for patients with the disease, and providing clinical advice for community-based oncologists.
Analysis of Hepatotoxicity Associated With TKIs in Solid Tumors
October 18th 2022Tanios S. Bekaii-Saab, MD, analyzes the common adverse events (AEs) associated with tyrosine kinase inhibitors (TKIs) across solid tumors, with a special focus on hepatotoxicity and the clinical implications of this AE for future clinical studies of TKIs in combination with immune checkpoint inhibitors.
Integrating Molecular Testing into Decision Making in NSCLC
October 12th 2022A panel of oncologists share insights on molecular testing in non-small cell lung cancer (NSCLC) and how they integrate and interpret the results to optimize treatment selection for their patients.
Sponsored in part by Takeda Oncology. Content independently developed by OncLive.
Evolving Approaches in the Management of Neuroendocrine Tumor-Associated Carcinoid Syndrome
September 13th 2022Satya (Nanu) Das, MD, MSCI, Rodney Pommier, MD, and Jerome Zacks, MD, discuss how patients with neuroendocrine tumors progress to carcinoid syndrome and carcinoid heart disease, and how strategies for management have changed after key clinical trial data.
Funding provided by TerSera Therapeutics LLC. Content independently developed by OncLive.
My Treatment Approach: Recent Advances in the Treatment of Multiple Myeloma in Early Relapse
August 18th 2022Brea Lipe, MD, and Peter Forsberg, MD, discuss updates in the treatment of R/R multiple myeloma, and present two hypothetical patient profiles to show how recent data can be incorporated into clinical practice.